Phase 3 Jupiter 02 Trial Nct03581786 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration. ....

Emory University , United States , Nabilf Saba , Junshi Biosciences , Coherus Biosciences , Howard Halpern , Shravan Kandula , Neck Cancer Multidisciplinary Program , Department Of Hematology , Neck Cancer Research , Medical Oncology , Emory University School , Howard Halpern Chair , Winship Cancer Institute , Adventhealth Medical Group Radiation Oncology , Central Florida , Shanghai Junshi , Chenq Y , Chend P , Pd 1 Inhibitor , Nasopharyngeal Carcinoma , Phase 3 Jupiter 02 Trial Nct03581786 , Phase 2 Polaris 02 Trial Nct02915432 ,